Latest Neurocutaneous Disorder Companies Update
August 2023: According to research published in JAMA Network Open, neurocutaneous disorders, which are already connected to cancer susceptibility and occasionally prenatal variables, were shown to be associated with an elevated risk of pediatric cancer, particularly central nervous system (CNS) malignancies. The study included more than 4.1 million children aged 20 and under from 1973 to 2015, whose data was obtained from the Swedish National Medical Birth Register (MBR) and examined between April 2021 and May 2023. According to the authors, there were several perinatal factors—high birth weight, being born large for gestational age, preterm birth, low 5-minute Apgar score, and large head circumference—that had less of an association with pediatric cancer, despite the fact that the associations existed prior to this study. After controlling for neurocutaneous disorders, these correlations remained unchanged.
October 2023: The Francis Crick Institute and the Great Ormond Street Hospital (GOSH)/UCL Great Ormond Street Institute of Child Health have identified new potential treatments for children with rare genetic blood vessel conditions that cause severe, lifelong, and disabling symptoms such as seizures and delayed development. The researchers demonstrated that calcium issues are at the root of these disorders in two publications published in the Journal of Investigative Dermatology. Stabilizing calcium levels in the brain might thus be a focus for novel medicines aimed at protecting the brain against long-term harm. "Mosaic mutations"—genetic abnormalities that present in some but not all cells of the body—in two genes, GNAQ or GNA11, cause a variety of disorders, including Sturge-Weber syndrome and Phakomatosis Pigmentovascularis with Dermal Melanocytosis (PPV-DM).
List of Neurocutaneous Disorder Key companies in the market
- Valeant Pharmaceuticals International, Inc. (U.S.)
- Allergan (U.S.)
- Syneron Medical Ltd (U.S.)
- Medtronic Plc (U.S.)
- Cutera, Inc. (U.S.)
- St Jude Medical, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Abbott Laboratories Inc. (U.S.)
- UCB S.A. (Belgium)
- Sanofi SA (France)
- Shire Plc (Ireland)Â
- F. Hoffmann-La Roche AG (Switzerland)
- Aleva Neurotherapeutics SA (Switzerland)
- Johnson & Johnson (U.S.)
